Shares of Apyx Medical APYX remained unaffected after the company reported Q3 results.
Quarterly Results
Earnings per share increased 15.38% over the past year to ($0.11), which beat the estimate of ($0.16).
Revenue of $6,954,000 declined by 8.20% from the same period last year, which beat the estimate of $5,680,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 09, 2020
Time: 08:00 AM
ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/40993/indexl.html
Technicals
52-week high: $8.59
52-week low: $2.81
Price action over last quarter: Up 15.22%
Company Description
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.